Hospital
Grant County Public Hospital District No. 3
Grant County Public Hospital District No. 3 was paid $8.83M by Medicaid between Jan 2018 and Nov 2024, across 79 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoGRANT COUNTY PUBLIC HOSPITAL DISTRICT NO. 3
EPHRATA, WA 98823
EPHRATA, WA 98823
33aNPI1811979610assigned 11/17/2005
33bProvider typeCritical Access Hospital
28Total paid$8.83M
24GClaims103,972
24DCodes billed79
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#17 of 30
Median peer was paid$9.10M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,202 | $998K | |
| 2019 | 15,083 | $1.09M | |
| 2020 | 12,969 | $1.01M | |
| 2021 | 13,809 | $1.12M | |
| 2022 | 16,134 | $1.50M | |
| 2023 | 15,160 | $1.34M | |
| 2024incomplete | 14,615 | $1.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 8,501 | 7,626 | $1.65M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 5,363 | 4,541 | $1.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 3,361 | 2,710 | $1.21M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.7% | 9,105 | 2,555 | $589K |
| 80305 | 4.4% | 2,142 | 1,967 | $385K | |
| 80053 | Comprehensive metabolic panel | 3.4% | 7,682 | 6,913 | $300K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.2% | 1,693 | 1,662 | $280K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 562 | 441 | $245K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 2,596 | 2,395 | $243K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 2,489 | 2,344 | $176K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 8,139 | 7,281 | $173K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 2,198 | 1,972 | $162K |
67 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 925 | $150K |
| 80050 | General health panel | 1.3% | 675 | $118K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,194 | $111K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 1,343 | $104K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 1,554 | $95K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,331 | $88K |
| 84484 | <1% | 1,770 | $79K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,898 | $75K |
| 80061 | Lipid panel | <1% | 1,110 | $71K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,649 | $64K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,138 | $63K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,804 | $62K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 532 | $61K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,303 | $60K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 517 | $55K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,745 | $51K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 706 | $50K |
| 84703 | <1% | 1,185 | $50K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,493 | $48K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,285 | $45K |
| 83690 | <1% | 1,296 | $45K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 51 | $45K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 809 | $44K |
| 81001 | <1% | 2,982 | $43K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,235 | $39K |
| 74178 | <1% | 33 | $37K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,037 | $32K |
| 83605 | <1% | 724 | $28K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,751 | $17K |
| 81000 | <1% | 1,294 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 478 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,574 | $14K |
| 87077 | <1% | 372 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 285 | $14K |
| 96376 | <1% | 200 | $10K | |
| 85379 | <1% | 153 | $10K | |
| 83880 | <1% | 118 | $10K | |
| 97161 | <1% | 91 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 218 | $9K |
| 86140 | <1% | 257 | $8K | |
| 87186 | <1% | 278 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 757 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 523 | $5K |
| 82962 | <1% | 279 | $5K | |
| 83735 | <1% | 241 | $5K | |
| 93041 | <1% | 209 | $4K | |
| 82150 | <1% | 179 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 301 | $3K |
| 85610 | <1% | 239 | $3K | |
| 97162 | <1% | 29 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25 | $2K |
| 87420 | <1% | 32 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 24 | $1K |
| 73630 | <1% | 13 | $997.23 | |
| 84439 | <1% | 14 | $804.71 | |
| 87040 | <1% | 24 | $794.05 | |
| 73562 | <1% | 18 | $614.84 | |
| 85378 | <1% | 27 | $555.54 | |
| 97035 | <1% | 23 | $420.76 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 60 | $402.06 |
| 85652 | <1% | 12 | $220.53 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12 | $110.22 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 21 | $73.09 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 86 | $73.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| A9270 | Non-covered item or service | 0% | 559 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBODI, CHERYL (EXECUTIVE ASSISTANT)